FBXW7 is an inclusion criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain FBXW7 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [4].

FBXW7 is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FBXW7 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FBXW7 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FBXW7 status and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FBXW7 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FBXW7 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains FBXW7 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].